Publications

Filters
April 17, 2018

The inhibitor of apoptosis protein (IAP) antagonist Debio 1143 enhances the immune response to anti-PD1/L1 inhibitors in vitro and in…

Read more
January 23, 2018

Safety and efficacy of the selective FGFR inhibitor Debio 1347 in phase 1 study patients with fgfr genomically activated advanced…

Read more
December 1, 2016

Chemosensitization to Carboplatin and Paclitaxel by IAP Inhibitor Debio 1143 in Ovarian Cancer Cell Lines: Signature Identification for Potential Patient…

Read more
October 29, 2016

Paclitaxel-Carboplatin With The Oral Iap Inhibitor Debio1143 In A Subset Of Patients With Recurrent Epithelial Ovarian Cancer (EOC): Phase I

Read more
June 21, 2016

Population pharmacokinetic analysis of the IAPs antagonist Debio 1143 and its major metabolite in oncologic patients

Read more
April 30, 2016

Phase 1 Study of Debio 1143 with Concurrent Chemo-Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Read more
April 21, 2016

FGFR selective inhibitor Debio1347 induces tumor regressions in FGFR2-altered gastric cancer PDX models

Read more
April 11, 2016

Activity of Debio 1452 against Staphylococcus spp. collected in 2013 / 2014

Read more
April 11, 2016

Activity of the novel Fabl inhibitor Debio 1452 against intracellular forms of susceptible and resistant S. aureus: comparison with linezolid,…

Read more